The data presented in this review clearly demonstrate how FDG-PET/CT will increasingly play a major role in the assessment of patients affected by a wide range of infectious diseases like osteomyelitis, infected prostheses, endocarditis, and even lung and CNS infections. FDG-PET has proven to be an excellent imaging modality not only for the diagnosis, but also for the staging and evaluation of treatment response overcoming many limitations associated with structural imaging techniques or conventional scintigraphic methodologies. The ability of FDG-PET to quantify disease activity seems particularly attractive, providing the possibility to avoid invasive diagnostic tests, to identify multifocal infection and to monitor early response to antibiotic treatment. At this juncture, FDG-PET should be used to improve the clinical management of infectious disorders although further validation with prospective randomized/controlled studies is strongly encouraged.
Papers of particular interest, published within the annual period of review, have been highlighted as:
1▪. Hess S, Alavi A, Basu S. PET-based personalized management of infectious and inflammatory disorders. PET Clin 2016; 11:351–361.
A review article regarding the role of FDG-PET/CT in the management of infectious and inflammatory disorders.
2. Kwee TC, Basu S, Alavi A. Letter: Opinion on favoring labeled leukocyte imaging over 18F-FDG-PET for diagnosing prosthetic joint infection: rectifying ongoing misconceptions. J Nucl Med 2016; [Epub ahead of print].
3. Basu S, Kwee TC, Saboury B, et al. FDG PET for diagnosing infection in hip and knee prostheses: prospective study in 221 prostheses and subgroup comparison with combined (111)In-labeled leukocyte/(99m)Tc-sulfur colloid bone marrow imaging in 88 prostheses. Clin Nucl Med 2014; 39:609–615.
4. Albarillo F, O’Keefe P. Opportunistic neurologic infections in patients with acquired immunodeficiency syndrome (AIDS). Curr Neurol Neurosci Rep 2016; 16:10.
5. Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS 1996; 7:337–346.
6. Menendez JA, Lilien DL, Nanda A, et al. Use of fluorodeoxyglucose-positron emission tomography for the differentiation of cerebral lesions in patients with acquired immune deficiency syndrome. Neurosurg Focus 2000; 8:1–4.
7. Villringer K, Jäger H, Dichgans M, et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr 1995; 19:532–536.
8. Westwood TD, Hogan C, Julyan PJ, et al. Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. Eur J Radiol 2013; 82:e374–e379.
9. Saiz A, Graus F. Neurologic complications of hematopoietic cell transplantation. Semin Neurol 2010; 30:287–295.
10. Gavaldà J, Meije Y, Fortún J, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect 2014; 20:27–48.
11. Shi X, Yi C, Wang X, et al. 13N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess. Clin Nucl Med 2015; 40:195–199.
12. Tseng J-R, Su Y-Y, Lee M-H, et al. Clinical usefulness of FDG PET/CT in the detection of unusual central nervous system infections. J Neurol Sci 2014; 345:244–247.
13. Schillaci O, Chiaravalloti A, Chiaravalloti A, et al. 18F-FDG PET/MR in herpes simplex virus encephalitis: a case study. Rev Esp Med Nucl E Imagen Mol 2014; 33:249–250.
14. Omer TA, Fitzgerald DE, Sheehy N, Doherty CP. Neurosyphilis presenting with unusual hippocampal abnormalities on magnetic resonance imaging and positron emission tomography scans: a case report. J Med Case Rep 2012; 6:389.
15. Altini C, Niccoli AA, Ferrari C, et al. (18)F-FDG PET/CT contribution to diagnosis and treatment response of rhino-orbital-cerebral mucormycosis. Hell J Nucl Med 2014; 18:68–70.
16. Jolepalem P, Wong C-YO. Neurocysticercosis on 18F-FDG PET/MRI: co-registered images. Clin Nucl Med 2014; 39:e110–e113.
17▪. Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. Int J Infect Dis 2015; 32:87–93.
A review describing imaging findings in both pulmonary and extrapulmonary tuberculosis, including FDG-PET/CT patterns.
18. Deppen SA, Blume JD, Kensinger CD, et al. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA 2014; 312:1227–1236.
19. Vorster M, Sathekge MM, Bomanji J. Advances in imaging of tuberculosis: the role of 18
F-FDG PET and PET/CT. Curr Opin Pulm Med 2014; 20:287–293.
20. Soussan M, Brillet P-Y, Mekinian A, et al. Patterns of pulmonary tuberculosis on FDG-PET/CT. Eur J Radiol 2012; 81:2872–2876.
21. Yago Y, Yukihiro M, Kuroki H, et al. Cold tuberculous abscess identified by FDG PET. Ann Nucl Med 2005; 19:515–518.
22. Martinez V, Castilla-Lievre MA, Guillet-Caruba C, et al. F-FDG PET/CT in tuberculosis: an early noninvasive marker of therapeutic response. Int J Tuberc Lung Dis 2012; 16:1180–1185.
23. Park YH, Yu CM, Kim ES, et al. Monitoring therapeutic response in a case of extrapulmonary tuberculosis by serial F-18 FDG PET/CT. Nucl Med Mol Imaging 2012; 46:69–72.
24. Hu N, Tan Y, Cheng Z, et al. FDG PET/CT in monitoring antituberculosis therapy in patient with widespread skeletal tuberculosis. Clin Nucl Med 2015; 40:919–921.
25. Dureja S, Sen IB, Acharya S. Potential role of F18 FDG PET-CT as an imaging biomarker for the noninvasive evaluation in uncomplicated skeletal tuberculosis: a prospective clinical observational study. Eur Spine J 2014; 23:2449–2454.
26. Arbind A, D′souza M, Jaimini A, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in response monitoring of extra-pulmonary tuberculosis. Indian J Nucl Med 2016; 31:59–61.
27. Chen RY, Dodd LE, Lee M, et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med 2014; 6: 265ra166.
28. Shejul Y, Chhajed PN, Basu S. 18F-FDG PET and PET/CT in diagnosis and treatment monitoring of pyrexia of unknown origin due to tuberculosis with prominent hepatosplenic involvement. J Nucl Med Technol 2014; 42:235–237.
29. Sharma P, Mukherjee A, Karunanithi S, et al. Potential role of 18F-FDG PET/CT in patients with fungal infections. AJR Am J Roentgenol 2014; 203:180–189.
30. Nakajima H, Sawaguchi H, Hoshi S, et al. [Intense 18F-fluorodeoxyglucose uptake due to allergic bronchopulmonary aspergillosis]. Arerugi 2009; 58:1426–1432.
31. Mucha K, Foroncewicz B, Orłowski T, et al. Atypical presentation of invasive pulmonary aspergillosis in a liver transplant recipient. Ann Transplant 2013; 18:238–242.
32. Garcia-Olivé I, Andreo F, Rosiñol O, et al. Bronchial stump aspergillosis after lobectomy for lung cancer as an unusual cause of false positive fluorodeoxyglucose positron emission tomography and computed tomography: a case report. J Med Case Rep 2011; 5:72.
33. Casal RF, Adachi R, Jimenez CA, et al. Diagnosis of invasive aspergillus tracheobronchitis facilitated by endobronchial ultrasound-guided transbronchial needle aspiration: a case report. J Med Case Rep 2009; 3:9290.
34. Ahn B-C, Lee S-W, Lee J, et al. Pulmonary aspergilloma mimicking metastasis from papillary thyroid cancer. Thyroid 2011; 21:555–558.
35. Baxter CG, Bishop P, Low SE, et al. Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. Thorax 2011; 66:638–640.
36. Kim JY, Yoo J-W, Oh M, et al. (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography findings are different between invasive and noninvasive pulmonary aspergillosis. J Comput Assist Tomogr 2013; 37:596–601.
37. Zhang Y, Li B, Shi H, et al. Sarcomatoid carcinoma of the lung mimics aspergilloma on 18
F-FDG PET/CT. Hell J Nucl Med 2015; 18:268–270.
38. Ozsahin H, von Planta M, Müller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 1998; 92:2719–2724.
39. Hot A, Maunoury C, Poiree S, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect 2011; 17:409–417.
40. Patterson TF, Thompson GR, Denning DW, et al. Executive summary: Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:433–442.
41. Denning DW. The ambitious ‘95–95 by 2025’ roadmap for the diagnosis and management of fungal diseases. Thorax 2015; 70:613–614.
42. Kono M, Yamashita H, Kubota K, et al. FDG PET imaging in pneumocystis pneumonia. Clin Nucl Med 2015; 40:679–681.
43. Lee C-H, Tzao C, Chang T-H, et al. Case of pulmonary cryptococcosis mimicking hematogeneous metastases in an immunocompetent patient: value of absent 18F-fluorodeoxyglucose uptake on positron emission tomography/CT scan. Korean J Radiol 2013; 14:540–543.
44. Guy JP, Raza S, Bondi E, et al. Cryptococcus pneumonia presenting in an immunocompetent host with pulmonary asbestosis: a case report. J Med Case Rep 2012; 6:170.
45. Wang J, Ju H-Z, Yang M-F. Pulmonary cryptococcosis and cryptococcal osteomyelitis mimicking primary and metastatic lung cancer in (18)F-FDG PET/CT. Int J Infect Dis 2014; 18:101–103.
46. Ghimire P, Sah AK. Pulmonary cryptococcosis and tuberculoma mimicking primary and metastatic lung cancer in 18F-FDG PET/CT. Nepal Med Coll J 2011; 13:142–143.
47. Qiu L, Lan L, Feng Y, et al. Pulmonary actinomycosis imitating lung cancer on (18)F-FDG PET/CT: a case report and literature review. Korean J Radiol 2015; 16:1262–1265.
48. Treglia G, Taralli S, Calcagni ML, et al. Is there a role for fluorine 18 fluorodeoxyglucose-positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review. J Comput Assist Tomogr 2011; 35:387–393.
49. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075–3128.
50. Millar BC, Prendergast BD, Alavi A, et al. 18FDG-positron emission tomography (PET) has a role to play in the diagnosis and therapy of infective endocarditis and cardiac device infection. Int J Cardiol 2013; 167:1724–1736.
51. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633–638.
52. Habib G, Derumeaux G, Avierinos J-F, et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol 1999; 33:2023–2029.
53. Hill EE, Herijgers P, Claus P, et al. Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome. Am Heart J 2007; 154:923–928.
54. Vieira MLC. Repeated echocardiographic examinations of patients with suspected infective endocarditis. Heart 2004; 90:1020–1024.
55. Saby L, Laas O, Habib G, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis. J Am Coll Cardiol 2013; 61:2374–2382.
56▪. Musso M, Petrosillo N. Nuclear medicine in diagnosis of prosthetic valve endocarditis: an update. BioMed Res Int 2015; 2015:127325.
A review of the available evidence regarding the role of nuclear medicine techniques, including FDG-PET/CT, in the diagnosis of prosthetic valve endocarditis.
57. Thuny F, Gaubert J-Y, Jacquier A, et al. Imaging investigations in infective endocarditis: current approach and perspectives. Arch Cardiovasc Dis 2013; 106:52–62.
58. Bonfiglioli R, Nanni C, Morigi JJ, et al. 18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. Eur J Nucl Med Mol Imaging 2013; 40:1190–1196.
59. Vind SH, Hess S. Possible role of PET/CT in infective endocarditis. J Nucl Cardiol 2010; 17:516–519.
60. Thomsen RW, Farkas DK, Friis S, et al. Endocarditis and risk of cancer: a Danish Nationwide Cohort Study. Am J Med 2013; 126:58–67.
61. Klug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation 2007; 116:1349–1355.
62. Sarrazin J-F, Philippon F, Tessier M, et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol 2012; 59:1616–1625.
63. Kwee TC, Basu S, Alavi A. Should the nuclear medicine community continue to underestimate the potential of 18F-FDG-PET/CT with present generation scanners for the diagnosis of prosthetic joint infection? Nucl Med Commun 2015; 36:756–757.
64. Termaat MF, Raijmakers PGHM, Scholten HJ, et al. The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-analysis. J Bone Joint Surg Am 2005; 87:2464–2471.
65. Wang G, Zhao K, Liu Z, et al. A meta-analysis of fluorodeoxyglucose-positron emission tomography versus scintigraphy in the evaluation of suspected osteomyelitis. Nucl Med Commun 2011; 32:1134–1142.
66▪▪. Prodromou ML, Ziakas PD, Poulou LS, et al. FDG PET is a robust tool for the diagnosis of spondylodiscitis: a meta-analysis of diagnostic data. Clin Nucl Med 2014; 39:330–335.
A meta-analysis supporting the use of FDG-PET/CT as a diagnostic test in suspected spondylodiscitis.
67. Gunes BY, Onsel C, Sonmezoglu K, et al. Diagnostic value of F-18 FDG PET/CT in patients with spondylodiscitis: is dual time point imaging time worthy? Diagn Microbiol Infect Dis 2016; 85:381–385.
68. Fuster D, Tomás X, Granados U, et al. Prospective comparison of whole-body (18)F-FDG PET/CT and MRI of the spine in the diagnosis of haematogenous spondylodiscitis: response to comments by Soussan. Eur J Nucl Med Mol Imaging 2015; 42:356–357.
69. Cobbaert K, Pieters A, Devinck M, et al. Brucellar spondylodiscitis: case report. Acta Clin Belg 2007; 62:304–307.
70. Abdul H, Abdul N, Nordin A. Dual time point imaging of FDG PET/CT in a tuberculous spondylodiscitis. Biomed Imaging Interv J 2010; 6:e18.
71. Ioannou S, Chatziioannou S, Pneumaticos SG, et al. Fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan contributes to the diagnosis and management of brucellar spondylodiskitis. BMC Infect Dis 2013; 13:73.
72. Smids C, Kouijzer IJE, Vos FJ, et al. A comparison of the diagnostic value of MRI and (18)F-FDG-PET/CT in suspected spondylodiscitis. Infection 2016; [Epub ahead of print].
73. Nanni C, Boriani L, Salvadori C, et al. FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. Eur J Nucl Med Mol Imaging 2012; 39:1538–1544.
74. Riccio SA, Chu AKM, Rabin HR, Kloiber R. Fluorodeoxyglucose positron emission tomography/computed tomography interpretation criteria for assessment of antibiotic treatment response in pyogenic spine infection. Can Assoc Radiol J 2015; 66:145–152.
75. Skanjeti A, Penna D, Douroukas A, et al. PET in the clinical work-up of patients with spondylodiscitis: a new tool for the clinician? Q J Nucl Med Mol Imaging 2012; 56:569–576.
76. Basu S, Chryssikos T, Moghadam-Kia S, et al. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med 2009; 39:36–51.
77. Chacko TK, Zhuang H, Stevenson K, et al. The importance of the location of fluorodeoxyglucose uptake in periprosthetic infection in painful hip prostheses. Nucl Med Commun 2002; 23:851–855.
78. Zoccali C, Teori G, Salducca N. The role of FDG-PET in distinguishing between septic and aseptic loosening in hip prosthesis: a review of literature. Int Orthop 2009; 33:1–5.
79. Odekerken JCE, Brans BT, Welting TJM, et al. (18)F-FDG microPET imaging differentiates between septic and aseptic wound healing after orthopedic implant placement: a longitudinal study of an implant osteomyelitis in the rabbit tibia. Acta Orthop 2014; 85:305–313.
80. Shemesh S, Kosashvili Y, Groshar D, et al. The value of 18-FDG PET/CT in the diagnosis and management of implant-related infections of the tibia: a case series. Injury 2015; 46:1377–1382.
81. Govaert GM, Glaudemans AWJM. Nuclear medicine imaging of posttraumatic osteomyelitis. Eur J Trauma Emerg Surg 2016; 42:397–410.
82. Brown TLY, Spencer HJ, Beenken KE, et al. Evaluation of dynamic [18
F]-FDG-PET imaging for the detection of acute postsurgical bone infection. PLoS One 2012; 7:e41863.
83. Nawaz A, Torigian DA, Siegelman ES, et al. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol 2010; 12:335–342.
84. Basu S, Chryssikos T, Houseni M, et al. Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infection? Nucl Med Commun 2007; 28:465–472.
85. Yang H, Zhuang H, Rubello D, et al. Mild-to-moderate hyperglycemia will not decrease the sensitivity of 18F-FDG PET imaging in the detection of pedal osteomyelitis in diabetic patients. Nucl Med Commun 2016; 37:259–262.
86. Kumar R, Karunanithi S, Zhuang H, Alavi A. Assessment of therapy response by FDG PET in infection and inflammation. PET Clin 2012; 7:233–243.
87. Basu S, Alavi A. Emerging role of FDG-PET for optimal response assessment in infectious diseases and disorders. Expert Rev Anti Infect Ther 2011; 9:143–145.
88. Lee P-I, Cheng G, Alavi A. The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis. J Nucl Cardiol 2016; [Epub ahead of print].